Let's see now, LL is 24% better than SOC, and remd

Quote:

---

Let's see now, LL is 24% better than SOC, and remdesivir is part of SOC, so LL is 24% better than remdesivir, and remdesivir has FDA EUA approval.

---

Exactly. And more importantly dexamethasone is SOC. LL is 24% better than that.

The issue is not the efficacy. The issue is the size of the trial and how few critical patients were in it. IMO we could/should still get an EUA in a/multiple countries. We will see.

But worst case scenario is we need more data. How fast do we think we can enroll now that we have actual data? Protip (faster than before)